Article

AMO launches new technology for phacoemulsification system

Advanced Medical Optics Inc. (AMO) introduced WhiteStar ICE technology for use with the Sovereign phacoemulsification system at the American Academy of Ophthalmology annual meeting in Chicago. The energy system/fluid management component allows surgeons to increase cutting power without increasing energy.

An initial "punch" at the beginning of each ICE pulse allows a gas-rich balanced salt solution to flow between the phaco tip and cataract material, acting as a transient cavitation accelerator, to improve cutting efficiency, according to the company.

Chamber Stabilization Environment (CASE) technology enables surgeons to optimize the use of fluidics during cataract removal while significantly reducing surge on occlusion break, AMO said in a prepared statement. Within milliseconds, the pre-programmed CASE settings proactively adjust vacuum before the occlusion breaks to reduce chamber shallowing significantly and maintain chamber stability, according to the company.

"The use of fluidics to complement ultrasound cataract extraction marks a paradigm shift that could allow surgeons to develop better techniques to improve patient outcomes," said Paul Rockley, AMO vice president, worldwide marketing, cataract equipment, Santa Ana, CA.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
© 2025 MJH Life Sciences

All rights reserved.